ALLMedicine™ Urinary Free Cortisol Center
Research & Reviews 245 results
https://doi.org/10.1080/13697137.2022.2158727
Climacteric : the Journal of the International Menopause ... Virtanen I, Polo-Kantola P et. al.
Jan 23rd, 2023 - This study aimed to use external sleep disturbance as a model to evaluate sleep architecture in climacteric women before and after menopausal hormone therapy (MHT). Seventeen perimenopausal and 18 postmenopausal women underwent a polysomnography p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733005
BMC Endocrine Disorders; Hataya Y, Okubo M et. al.
Dec 11th, 2022 - The corticotropin-releasing hormone (CRH) challenge test can distinguish the disorders of the hypothalamus from those of the pituitary. However, the pathophysiology of hypothalamic disorder (HD) has not been fully understood. This study aimed to e...
https://doi.org/10.1210/clinem/dgac691
The Journal of Clinical Endocrinology and Metabolism; Dormoy A, Haissaguerre M et. al.
Dec 6th, 2022 - Prospective studies have demonstrated the efficacy of osilodrostat in Cushing's disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing's syndrome/ectopic ACTH syndrome (PNCS/EAS). Evaluate in France the re...
https://clinicaltrials.gov/ct2/show/NCT03842917
Nov 8th, 2022 - Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of beva...
https://doi.org/10.1111/cen.14835
Clinical Endocrinology; Sailer CO, Kuehne JM et. al.
Oct 21st, 2022 - Primary polydipsia is characterized by excessive fluid intake which may suppress vasopressin levels. It is speculated that suppressed vasopressin levels lead to a dysregulated hypothalamic-pituitary-adrenal (HPA) axis as vasopressin co-modulates t...
Drugs 6 results see all →
Clinicaltrials.gov 14 results
https://clinicaltrials.gov/ct2/show/NCT03842917
Nov 8th, 2022 - Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of beva...
https://clinicaltrials.gov/ct2/show/NCT02160730
Nov 4th, 2021 - To date, R-roscovitine (seliciclib) has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients. Studies included a Phase I study in which single agent seliciclib was adminis...
https://clinicaltrials.gov/ct2/show/NCT05089344
Oct 22nd, 2021 - Patients are recruited from the attendee of the Infertility clinic and IVF unit in maternity hospital Ain shams university who are eligible for the trial. Procedure will be done by Prof . Dr Mostafa Fouad . and Lecturer Dr Ebtihal ElTaieb * Proper...
https://clinicaltrials.gov/ct2/show/NCT03974789
Oct 5th, 2021 - Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory. They can be used to define robust diagnostic thresholds for salivary cor...
https://clinicaltrials.gov/ct2/show/NCT02297945
Sep 25th, 2020 - This study will include Cushing disease patients with persistent or recurrent disease (after pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to defer surgery. It will also include patients with ectopic AC...
News 35 results
https://www.medpagetoday.com/endocrinology/steroids/96481
Jan 4th, 2022 - The FDA approved a new treatment for adults with endogenous hypercortisolemia related to Cushing's syndrome, Xeris Biopharma announced late last week. The oral drug levoketoconazole (Recorlev) is indicated for the treatment of endogenous hypercort...
https://www.medpagetoday.com/endocrinology/generalendocrinology/92027
Apr 11th, 2021 - Women with obesity may have a higher risk of heavier periods due to delayed endometrial repair. "Although it is difficult to make strong recommendations based on this study alone, a common-sense approach would be to offer weight-loss support to wo...
https://www.mdedge.com/endocrinology/article/237622/hypercortisolism/metyrapone-cushings-syndrome-safe-effective-first-test
Mitchel L. Zoler, PhD
Mar 24th, 2021 - Metyrapone, an inhibitor of endogenous adrenal corticosteroid synthesis currently used in U. S.
https://www.medpagetoday.com/endocrinology/generalendocrinology/87394
Jul 3rd, 2020 - The FDA approved octreotide (Mycapssa) capsules for long-term maintenance of acromegaly in those already treated with octreotide or lanreotide, Chiasma announced. Certain medication and medical devices may inadvertently expose patients to harmful ...
https://www.medpagetoday.com/endocrinology/generalendocrinology/82567
Oct 4th, 2019 - New phase III clinical trial data suggests that an investigational oral drug, levoketoconazole, might be a useful therapeutic option for patients with Cushing syndrome, the study's authors said. The open-label, non-randomized trial included 94 pat...